Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.

Wang, Rutao; Wu, Sijing; Gamal, Amr; Gao, Chao; Hara, Hironori; Kawashima, Hideyuki; Ono, Masafumi; van Geuns, Robert-Jan; Vranckx, Pascal; Windecker, Stephan; Onuma, Yoshinobu; Serruys, Patrick W; Garg, Scot (2021). Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European heart journal. Cardiovascular pharmacotherapy, 7(6), pp. 547-556. Oxford University Press 10.1093/ehjcvp/pvab035

[img]
Preview
Text
Aspirin-free.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (959kB) | Preview

Historically, aspirin has been the primary treatment for the prevention of ischaemic events in patients with coronary artery disease. For patients undergoing percutaneous coronary intervention (PCI) standard treatment has been 12 months of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, followed by aspirin monotherapy; however, DAPT is undeniably associated with an increased risk of bleeding. For over a decade novel P2Y12 inhibitors, which have increased specificity, potency, and efficacy have been available, prompting studies which have tested whether these newer agents can be used in aspirin-free antiplatelet regimens to augment clinical benefits in patients post-PCI. Among these studies, the GLOBAL LEADERS trial is the largest by cohort size, and so far has provided a wealth of evidence in a variety of clinical settings and patient groups. This article summarizes the state-of-the-art evidence obtained from the GLOBAL LEADERS and other trials of aspirin-free strategies.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2055-6845

Publisher:

Oxford University Press

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

20 Jan 2022 14:46

Last Modified:

27 Apr 2024 04:47

Publisher DOI:

10.1093/ehjcvp/pvab035

PubMed ID:

33930107

Uncontrolled Keywords:

GLOBAL LEADERS P2Y12 inhibitor Percutaneous coronary intervention Randomized clinical trials  Aspirin-free therapy

BORIS DOI:

10.48350/163209

URI:

https://boris.unibe.ch/id/eprint/163209

Actions (login required)

Edit item Edit item
Provide Feedback